Tim Grob

1.7k total citations · 1 hit paper
18 papers, 423 citations indexed

About

Tim Grob is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Tim Grob has authored 18 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Tim Grob's work include Acute Myeloid Leukemia Research (17 papers), Protein Degradation and Inhibitors (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Tim Grob is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Protein Degradation and Inhibitors (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Tim Grob collaborates with scholars based in Netherlands, Belgium and Switzerland. Tim Grob's co-authors include Peter J.M. Valk, Mojca Jongen‐Lavrencic, Bob Löwenberg, Gert J. Ossenkoppele, Melissa Rijken, Mathijs A. Sanders, Patrycja Gradowska, Marinus van Marwijk Kooy, H. Berna Beverloo and François G. Kavelaars and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cardiovascular Research.

In The Last Decade

Tim Grob

17 papers receiving 421 citations

Hit Papers

Molecular characterization of mutant TP53 acute myeloid l... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
    2022 159 citations Tim Grob, Adil S. A. Al Hinai et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Grob Netherlands 7 309 190 98 52 49 18 423
Babu Rao Vundinti India 13 180 0.6× 219 1.2× 106 1.1× 74 1.4× 33 0.7× 50 406
Liat Rainis Israel 5 295 1.0× 217 1.1× 69 0.7× 37 0.7× 132 2.7× 6 419
Kim-Hien T. Dao United States 10 303 1.0× 309 1.6× 190 1.9× 52 1.0× 31 0.6× 13 566
Monika J. Stankiewicz United States 7 171 0.6× 171 0.9× 90 0.9× 30 0.6× 33 0.7× 11 336
Matthew Ndonwi United States 9 242 0.8× 318 1.7× 109 1.1× 57 1.1× 30 0.6× 11 486
Antoine Crinquette France 3 200 0.6× 156 0.8× 87 0.9× 49 0.9× 72 1.5× 4 352
Masuzu Ueda Japan 8 227 0.7× 191 1.0× 128 1.3× 30 0.6× 25 0.5× 19 410
Marianne Eyholzer Switzerland 7 279 0.9× 307 1.6× 119 1.2× 163 3.1× 61 1.2× 8 520
Colin Grace United Kingdom 13 252 0.8× 158 0.8× 188 1.9× 46 0.9× 55 1.1× 20 463
Mariam G. Aslanyan Netherlands 6 369 1.2× 536 2.8× 172 1.8× 104 2.0× 38 0.8× 8 708

Countries citing papers authored by Tim Grob

Since Specialization
Citations

This map shows the geographic impact of Tim Grob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Grob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Grob more than expected).

Fields of papers citing papers by Tim Grob

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Grob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Grob. The network helps show where Tim Grob may publish in the future.

Co-authorship network of co-authors of Tim Grob

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Grob. A scholar is included among the top collaborators of Tim Grob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Grob. Tim Grob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Havermans, Marije, Roger Mulet‐Lazaro, Leonie Smeenk, et al.. (2025). MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia. Blood. 146(25). 3098–3105.
2.
Grob, Tim, Melissa Rijken, François G. Kavelaars, et al.. (2024). Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML. Blood Advances. 9(5). 1069–1077. 2 indexed citations
3.
Kavelaars, François G., et al.. (2024). Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA. HemaSphere. 8(8). e141–e141. 1 indexed citations
4.
Zeilemaker, Annelieke, Melissa Rijken, François G. Kavelaars, et al.. (2024). Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis. Blood Advances. 9(6). 1344–1355. 2 indexed citations
5.
Grob, Tim, Adil S. A. Al Hinai, Mathijs A. Sanders, et al.. (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 139(15). 2347–2354. 159 indexed citations breakdown →
6.
Grob, Tim, Mathijs A. Sanders, François G. Kavelaars, et al.. (2022). Poster: AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 22. S131–S131. 1 indexed citations
7.
Grob, Tim, Mathijs A. Sanders, Melissa Rijken, et al.. (2022). Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. Journal of Clinical Oncology. 41(4). 756–765. 69 indexed citations
8.
Grob, Tim, Mathijs A. Sanders, François G. Kavelaars, et al.. (2022). AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 22. S227–S227. 1 indexed citations
9.
Smeenk, Leonie, Roger Mulet‐Lazaro, Anja Ebert, et al.. (2021). Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia. Cancer Discovery. 11(11). 2868–2883. 29 indexed citations
10.
Hellesøy, Monica, et al.. (2021). Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Molecular Oncology. 15(9). 2285–2299. 7 indexed citations
11.
Hellesøy, Monica, Tim Grob, Adil Al Hinai, et al.. (2021). FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology. 15(9). 2300–2317. 6 indexed citations
12.
Hinai, Adil S. A. Al, Tim Grob, Melissa Rijken, et al.. (2021). PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse. Leukemia. 35(9). 2693–2697. 6 indexed citations
13.
Norden, Yvette van, Michel van Gelder, Dimitri Breems, et al.. (2020). Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. Blood Advances. 4(18). 4430–4437. 22 indexed citations
14.
Mulet‐Lazaro, Roger, H. Berna Beverloo, Claudia Erpelinck-Verschueren, et al.. (2020). Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. Blood. 136(2). 224–234. 44 indexed citations
15.
Mulet‐Lazaro, Roger, Berna Beverloo, Marije Havermans, et al.. (2018). Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression. Blood. 132(Supplement 1). 2766–2766. 1 indexed citations
16.
Jongen‐Lavrencic, Mojca, Tim Grob, François G. Kavelaars, et al.. (2017). Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML. Blood. 130(Suppl_1). LBA–5. 3 indexed citations
17.
Grob, Tim, François G. Kavelaars, Mario Bargetzi, et al.. (2016). Mutant NPM1 MRD and FLT3-ITD Status are Independent Prognostic Factors for the Risk of Relapse in AML Patients. Clinical Lymphoma Myeloma & Leukemia. 16. S31–S32. 1 indexed citations
18.
Szulcek, Robert, Cora Beckers, Jelle de Wit, et al.. (2013). Localized RhoA GTPase activity regulates dynamics of endothelial monolayer integrity. Cardiovascular Research. 99(3). 471–482. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Babu Rao Vundinti Breakdown of academic impact, for papers by Liat Rainis Breakdown of academic impact, for papers by Kim-Hien T. Dao Breakdown of academic impact, for papers by Monika J. Stankiewicz Breakdown of academic impact, for papers by Matthew Ndonwi Breakdown of academic impact, for papers by Antoine Crinquette Breakdown of academic impact, for papers by Masuzu Ueda Breakdown of academic impact, for papers by Marianne Eyholzer Breakdown of academic impact, for papers by Colin Grace Breakdown of academic impact, for papers by Mariam G. Aslanyan
Rankless by CCL
2026